(firstQuint)Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions.

 open label, randomized, two-treatment, three-period, three-sequence, partial replicate oral bioequivalence study of Lansoprazole 30 mg DR Capsules of Dr.

Reddy's Laboratories Limited, India comparing with that of PREVACID(R) (containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc.

 USA, in healthy, adult, human subjects under fasting conditions.

 48 healthy, adult, human subjects were enrolled in the study and 42 subjects were completed the study.

.

 Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions@highlight

The objective of this study was to compare the relative bioavailability of Lansoprazole DR Capsules 30 mg with Prevacid(R) Capsules 30 mg under fasting conditions in healthy adult human subjects.

